Labcorp(US:LH) Prnewswireยท2025-04-29 10:50Core Insights - Labcorp reported solid performance in Q1 2025, with a revenue increase of 5.3% year-over-year, reaching $3.35 billion, while adjusted EPS rose to $3.84 from $3.68 in the previous year [5][7][40] - The company updated its full-year guidance, maintaining revenue growth expectations of 6.7% to 8.0% and adjusted EPS range of $15.70 to $16.40, with the midpoint raised by $0.05 [23][24] Financial Performance - Revenue for Q1 2025 was $3.35 billion, compared to $3.18 billion in Q1 2024, reflecting a 5.3% increase [5][7] - Adjusted EPS for Q1 2025 was $3.84, up from $3.68 in Q1 2024, while diluted EPS decreased to $2.52 from $2.69 [5][40] - Operating income for Q1 2025 was $326 million, slightly up from $321.3 million in Q1 2024, with adjusted operating income at $469 million, compared to $452.8 million in the previous year [8][40] Cash Flow and Capital Allocation - Operating cash flow improved to $18.5 million in Q1 2025 from a negative $29.8 million in Q1 2024 [10][37] - The company invested $210.5 million in acquisitions and partnerships during the quarter and paid out $61.6 million in dividends [12][37] Strategic Initiatives - Labcorp entered a strategic collaboration with Inspira Health to manage hospital laboratory operations and acquired assets from BioReference Health and North Mississippi Health Services [6][12] - New tests introduced include Labcorp Plasma Complete for cancer and pTau-217/Beta Amyloid 42 Ratio for Alzheimer's diagnosis, expanding the test menu in oncology and neurology [5][6] Market Position and Outlook - Labcorp continues to position itself as a partner of choice for hospitals and health systems, leveraging science and technology to enhance its service offerings [3][5] - The company anticipates ongoing growth in diagnostics and drug development, supported by its strategic acquisitions and partnerships [3][23]